Potential therapeutic approaches are the administration of PN enriched with omega-3 fatty acids (which have been shown to diminish hepatic steatosis as a result of their anti-inflammatory effects), and the application of GLP-2 analogues or chyme reinfusions (which increase intestinal absorption and thereby lead to reduced reliance on parenteral support [2,28,29]). The gene discussed is GCG; the disease is Hepatic steatosis.